What Kliofem Treats: Main Uses and Benefits

Kliofem is utilized in Hormone Replacement Therapy (HRT) to manage symptoms associated with menopause. It is intended for the mitigation of bothersome symptoms resulting from estrogen deficiency in postmenopausal women who have an intact uterus. The medication helps address a range of symptoms, including hot flushes, night sweats, and vaginal dryness. It may also assist in addressing related issues such as mood changes and sleep disturbance. The primary therapeutic goal for patients is the alleviation of these disruptive menopausal symptoms and may contribute to supporting a sense of well-being. Common clinical contexts involve women who are experiencing a variety of moderate to substantial menopausal symptoms.

Quick Fact: Relief for Hot Flushes

Kliofem is officially intended for postmenopausal women who still have an intact uterus and whose natural menstrual periods ceased more than one year ago. The requirement for the uterus is due to the inclusion of norethisterone acetate, which counters the effects of oestrogen on the womb lining. The experience in treating women older than 65 years is limited, and the medicine is not indicated for children or adolescents.

Contraindications (Must Not Use)

Official regulatory labeling dictates that Kliofem is contraindicated and must not be used by individuals with:

• A history of, or known/suspected, breast cancer or any other oestrogen-dependent malignant tumour.
• Current or previous venous or arterial thromboembolism (e.g., DVT, pulmonary embolism, heart attack, stroke).
• Untreated endometrial hyperplasia or undiagnosed genital bleeding.
• Acute liver disease or unrecovered liver function abnormalities.
• Known thrombophilic disorders or porphyria.
• The medicine is also contraindicated during pregnancy and is not indicated during lactation.

Eligibility-Related Restrictions

Caution and close monitoring are required if the patient has conditions such as hypertension, diabetes mellitus, migraine, gallstones, or pre-existing uterine fibroids.

The hormonal components of Kliofem (Estradiol and Norethisterone acetate) are primarily metabolized by the Cytochrome P450 3A4 (CYP3A4) enzyme system. This metabolic pathway forms the basis of the most widely documented drug-drug interactions, as specified in regulatory labeling.

Metabolic Interactions Affecting Hormone Levels

Co-administration of medicines that induce (increase the activity of) the CYP3A4 enzyme may result in a significant reduction in the plasma concentrations of the active hormones. Substances that induce this enzyme include certain anticonvulsants (such as Phenobarbital or Carbamazepine) and anti-infectives (like Rifampicin). The herbal product St. John's Wort (Hypericum perforatum) is also documented as a potent enzyme inducer that may decrease hormone exposure.

Conversely, medicines that inhibit the CYP3A4 enzyme may lead to increased hormone plasma concentrations. This class includes certain antifungals (like Ketoconazole), macrolide antibiotics (Clarithromycin), and HIV protease inhibitors (Ritonavir). Consumption of Grapefruit juice can similarly exert an inhibitory effect on this metabolic pathway.

Other Documented Interactions

Regulatory documents specify that the estrogen component of Kliofem increases the levels of Thyroid Binding Globulin (TBG). This pharmacodynamic effect requires the monitoring of thyroid function and may necessitate an adjustment to the dose of co-administered thyroid replacement therapy. Furthermore, because hormonal therapy increases the risk of venous thromboembolism (VTE), co-administration with procoagulant agents, such as antifibrinolytics (e.g., Tranexamic Acid), is associated with an augmented risk of thrombosis.

Kliofem is a continuous combined hormonal product containing estradiol and norethisterone acetate. Both components are lipophilic compounds that passively diffuse across target cell membranes and interact with their respective intracellular nuclear receptors: the Estrogen Receptor (ER) and the Progesterone Receptor (PR).

Upon ligand binding, the receptor-ligand complex undergoes a conformational change, dimerizes, translocates into the nucleus, and binds to specific DNA sequences known as Hormone Response Elements (HREs) located in the promoter regions of target genes. This binding event modulates gene transcription, resulting in an altered pattern of messenger RNA (mRNA) and subsequent protein synthesis.

Estradiol acts as an agonist at the ER, primarily targeting tissues such as the bone and the central nervous system, leading to a modulation of gene expression responsible for bone remodeling and thermoregulatory function. Norethisterone acetate is a progestagen agonist that binds to the PR, selectively accumulating in endometrial tissue. Its primary action is to oppose the proliferative transcriptional effects of estradiol in the endometrium, instead inducing secretory and differentiative changes. This counter-regulatory action maintains endometrial stability, resulting in an overall systemic modulation of steroid-sensitive gene expression in multiple organ systems.

How to Use Kliofem

Kliofem is administered using a continuous combined regimen via the oral route. The prescribed dosage is one film-coated tablet taken once daily. Each tablet delivers a fixed-dose combination of Estradiol 2 mg and Norethisterone acetate 1 mg, which serves as both the starting and maintenance dose. The standard schedule requires uninterrupted daily ingestion, meaning the medicine is taken every day without breaks between packs.

For proper administration, the tablet should be swallowed whole with water; it must not be crushed or chewed. The tablet can be taken with or without food, but taking it at the same time every day is preferred to maintain consistency.

The procedure for a missed dose involves taking the tablet within 12 hours of the usual time if it is forgotten. If more than 12 hours have passed, the missed dose is discarded, and the next tablet should be taken at the normal time; a double dose must not be taken. In terms of the overall course, the treatment is typically used at the lowest effective dose for the shortest duration necessary. When initiating treatment, it can be started on any convenient day, unless switching from a sequential regimen, in which case administration begins immediately following the withdrawal bleeding.

Research Evidence / Overview of Studies for Kliofem

Evidence for Use in Managing Vasomotor Symptoms

Research exploring the effects of Kliofem (or its class), which belongs to the class of combined Hormone Replacement Therapy (HRT), primarily relies on Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time in postmenopausal women with an intact uterus who were experiencing outcomes related to physical discomfort, such as frequent hot flushes and disruptive night sweats. The trials were designed to examine symptom intensity or variability over relatively short periods, often lasting from a few weeks up to a year.

During these defined time intervals, studies monitored outcomes capturing phases of heightened symptom activity. Studies contribute to the broader evidence landscape, and findings describe patterns observed in the studies, including how patients reported their experience. Reported outcomes were assessed during short- to intermediate-term follow-up periods.

---

Evidence for Use in Preventing Postmenopausal Osteoporosis

Kliofem was also evaluated in research that explores outcomes specifically concerning the risk of osteoporotic fractures in postmenopausal women. The evidence for this indication is drawn from large-scale studies, including long-term RCTs and observational cohort studies, which focused on the combined HRT class. These studies monitored outcomes describing episodic or acute changes linked to bone health.

Research examined changes in Bone Mineral Density (BMD), a metric used to monitor skeletal health. Over observation periods of several years, studies monitored the incidence of osteoporotic fractures at sites like the hip and spine. The findings indicate data show patterns related to these long-term skeletal outcomes. This evidence highlights what is known and what is still uncertain regarding these long-term skeletal outcomes in women studied. The regulatory context for this use is specific, often reserved for women with high fracture risk.

---

What is Still Uncertain About Kliofem Research

Despite the availability of RCTs and supporting observational studies, some areas remain incompletely characterized. There is limited information for long-term outcomes and the sustained symptomatic response beyond the typical one-year study period. Data for certain groups, such as those initiating treatment late after menopause, remain insufficient, meaning that the full picture of the evidence for these specific subgroups is uncertain.

The evidence highlights what is known and what is still uncertain; research does not determine whether an individual will respond similarly. Consequently, the certainty remains low in areas where long-term or specific sub-group data are needed, and research is ongoing to address these limitations.

Key Studies & References

1. NIH DailyMed Label: Estradiol and Norethindrone Acetate Tablets (Kliofem equivalent)

Common questions about Kliofem (FAQ)

Q: What are the main benefits of taking Kliofem?

A: According to official product information, Kliofem is prescribed for Hormone Replacement Therapy (HRT) to help alleviate symptoms that arise from oestrogen deficiency following menopause. It is also indicated for the prevention of osteoporosis in postmenopausal women who are considered to be at a high risk of future fractures.

Q: How quickly does Kliofem start to relieve menopause symptoms?

A: Relief of menopausal symptoms, such as hot flushes and night sweats, is generally achieved within the first few weeks of starting Kliofem treatment. A healthcare provider should be consulted if symptoms persist or do not improve.

Q: Does Kliofem cause weight gain?

A: Yes, regulatory documents list weight gain as a common undesirable effect of Kliofem, affecting 1 to 10 in every 100 users. This is a recognized effect in the drug class.

Q: Can Kliofem affect my mood or cause anxiety?

A: Official product information lists depression as a common undesirable effect. Official documentation for Kliofem and related HRTs also mentions nervousness and anxiety as reported side effects.

Q: Is Kliofem suitable for women who have had a hysterectomy?

A: Kliofem is a combined HRT designed for women who still have an intact uterus (womb). The progestagen component (norethisterone acetate) is included specifically to protect the womb lining from the stimulating effects of oestrogen.

Q: How long can a woman typically stay on Kliofem?

A: Regulatory guidance on HRT states that treatment should be used at the lowest effective dose for the shortest duration necessary to achieve symptom relief. The necessity for continued treatment is subject to regular medical assessment.

Q: Can Kliofem be started years after menopause?

A: Kliofem is intended for postmenopausal women. The official warnings state that clinical experience is limited for treating women older than 65 years, which is a factor considered when initiating treatment long after menopause.

Q: Are there any dietary restrictions while taking Kliofem?

A: While there are no general dietary restrictions, the official product information notes that the medicine's action is affected by the enzyme system that metabolizes it. Grapefruit juice can interfere with this system.

Q: Does Kliofem affect bone density?

A: The oestrogen component in Kliofem helps prevent the bone loss that occurs after menopause. Clinical studies suggest that Kliofem can help prevent bone loss at key sites like the hip and spine compared to women not receiving treatment.

Q: What are the less common, but serious, side effects of Kliofem I should be aware of?

A: Official safety information documents an increased risk of serious conditions associated with HRT use, including breast cancer, certain other cancers, stroke, coronary artery disease, and venous thromboembolism (VTE), which are blood clots.

Q: Does Kliofem have an impact on libido?

A: Official reports mention that changes in sexual desire, including reduced libido, have been reported as a rare side effect with Kliofem or other hormone replacement therapies.

Q: Can I drink alcohol while taking Kliofem?

A: There is no explicit contraindication for consuming alcohol in the regulatory documentation. However, alcohol consumption may affect hormone levels.

Q: What ingredients are in Kliofem besides the hormones?

A: In addition to the active hormones, estradiol and norethisterone acetate, the tablets contain inactive ingredients called excipients. The official list of excipients specifies the presence of lactose monohydrate.

Q: Why did my doctor switch me from cyclical HRT to Kliofem?

A: Kliofem is a continuous combined HRT regimen, which is often chosen when the goal is to avoid the regular, menstrual-like withdrawal bleeding that occurs with cyclical or sequential HRT regimens.

Q: Is it normal to feel a bit nauseous when first starting Kliofem?

A: Nausea is listed as a common undesirable effect of Kliofem, affecting up to 10 in 100 users. Official reporting lists nausea as a common undesirable effect.

Q: Does Kliofem have any impact on vision or eye health?

A: Changes to sight, including dry eyes or changes to the tear film composition, have been reported as side effects with this class of medicine in official documents.

Q: Can Kliofem cause headaches or migraines to become worse?

A: Headache is a common side effect and migraine is an uncommon side effect. Official warnings note that the development of a new onset of migraine-like headaches or a significant increase in blood pressure is a condition that requires medical attention.

Q: Are there different strengths available for Kliofem?

A: Kliofem is a fixed-dose combination product containing estradiol and norethisterone acetate. Other products in the same line, such as Kliovance, are available in different strengths.

Q: What age group is Kliofem typically prescribed for?

A: Kliofem is intended for postmenopausal women whose natural periods ceased more than one year ago. Warnings note that clinical experience in women older than 65 years is limited.

Q: What kind of monitoring is needed while taking Kliofem?

A: Before starting Kliofem, a doctor must conduct a full physical examination and medical history. Regular follow-up examinations are required, including checks of the breasts and cervical smears, throughout the course of treatment.

Q: Can Kliofem be used by women who have had certain types of cancer in the past?

A: Official safety information states that Kliofem is strictly contraindicated and must not be used if a patient has a history of, or known/suspected, breast cancer or any other oestrogen-dependent malignant tumour.

Q: Are there any long-term side effects associated with Kliofem?

A: Official warnings specify that the risk of certain serious conditions, particularly breast cancer and venous thromboembolism (blood clots), increases with the duration of use of Hormone Replacement Therapy.

Q: What is the difference between Kliofem and Kliovance?

A: Both are continuous combined HRTs from the same manufacturer, but they are different strengths. Kliofem contains a higher dose of both active ingredients compared to Kliovance.

Q: Does Kliofem help with sleep disturbances related to menopause?

A: Kliofem is used to treat the symptoms of oestrogen deficiency. The therapy is commonly prescribed for hot flushes and night sweats, which are known causes of sleep disturbance during menopause.

Q: Is Kliofem a treatment for vaginal dryness?

A: Yes, as Kliofem provides hormonal substitution to alleviate symptoms of oestrogen deficiency, and the oestrogen component is known to relieve local symptoms such as vaginal itching and dryness.

Q: What are the signs that Kliofem is starting to work?

A: The primary sign that Kliofem is starting to work is the alleviation of menopausal symptoms. This includes a reduction in the frequency and severity of vasomotor symptoms like hot flushes and night sweats, typically noticeable within the first few weeks.

How to Store and Dispose of Kliofem?

Kliofem tablets must be stored according to official regulatory specifications to maintain the labeled 4-year shelf-life.

---

Storage Conditions

Requirement	Official Regulatory Statement
Temperature	The product must not be refrigerated or frozen.
Protection	Keep the container in the outer carton to protect the tablets from light.
Child Safety	Store the medicine out of the sight and reach of children.

---

Disposal Instructions

Official instructions require that any unused or expired Kliofem must be disposed of in accordance with local requirements.

Medicines should never be disposed of via household trash or wastewater, such as flushing down a toilet or pouring down a sink. Instead, return unwanted medication to a pharmacy or designated local collection point for safe disposal to protect the environment.